术前全身免疫炎症指数对胃肠道癌症患者的预后价值。
Prognostic value of pretreatment systemic immune-inflammation index in patients with gastrointestinal cancers.
机构信息
Department of General Surgery, The First People's Hospital of Neijiang, Neijiang, Sichuan, China.
Department of Hepatobiliary Surgery, The First Affiliated Hospital of Hainan Medical College, Haikou, Hainan, China.
出版信息
J Cell Physiol. 2019 May;234(5):5555-5563. doi: 10.1002/jcp.27373. Epub 2018 Oct 23.
BACKGROUND
Numerous studies have reported the relationship between systemic immune-inflammation index (SII) and prognosis in gastrointestinal (GI) cancers, but no consensus has been reached. We aimed to systematically evaluate the prognostic value of SII in patients with GI cancers.
METHODS
Relevant published papers regarding the prognostic value of SII in patients with GI cancers were obtained from a number of electronic databases. The overall hazard ratios and the corresponding 95% confidence intervals (95% CIs) were calculated using a fixed or random effects model to assess the relationship between SII and prognosis through Stata SE 12.0.
RESULTS
A total of 24 eligible published articles with 9,626 patients were included. From the pooled results, we found that high SII indicated worse overall survival (OS) in patients with GI cancers (HR = 1.52, 95%CI: 1.29-1.74). And patients with high SII had poorer disease-free survival (HR: 2.28, 95% CI: 1.46-3.10), time to recurrence (HR: 1.70, 95% CI: 1.11-2.30), and recurrence-free survival (HR: 1.60, 95% CI: 1.19-2.00) when compared with those with low SII values.
CONCLUSIONS
SII might serve as a noninvasive and powerful tool for predicting survival outcome in patients with GI cancers.
背景
许多研究报告了全身免疫炎症指数（SII）与胃肠道（GI）癌症预后之间的关系，但尚未达成共识。我们旨在系统评估 SII 对 GI 癌症患者预后的预测价值。
方法
从多个电子数据库中获取了有关 SII 对 GI 癌症患者预后价值的相关已发表文献。使用固定或随机效应模型计算总体危险比和相应的 95%置信区间（95%CI），以使用 Stata SE 12.0 通过评估 SII 与预后之间的关系。
结果
共纳入 24 篇符合条件的已发表文献，包含 9626 名患者。汇总结果表明，高 SII 表明 GI 癌症患者的总体生存率（OS）更差（HR=1.52，95%CI：1.29-1.74）。与 SII 值较低的患者相比，SII 值较高的患者无病生存率（HR：2.28，95%CI：1.46-3.10）、复发时间（HR：1.70，95%CI：1.11-2.30）和无复发生存率（HR：1.60，95%CI：1.19-2.00）更差。
结论
SII 可能成为预测 GI 癌症患者生存结局的一种非侵入性且强大的工具。
Zotero 插件